Alzinova AB

Targets Alzheimers with unique vaccine

Alzinova conducts research and development of drugs for the treatment of Alzheimer's disease, one of the world's largest public diseases. The company's patented technology enables the development of new therapies with the potential for large accuracy attack the harmful substances that are central to the onset of the disease.

Phase: Accelerator
Impact:
A long-acting drug for treatment and prevention of Alzheimer’s
CEO:
Per Wester
GUV Contact: Klementina Österberg